EUVIMEDEUVIMED entdecken
Crossref

Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma

Yan-Dong Su, Ru Ma, Yu-Bin Fu, He-Liang Wu, Xin-Li Liang, Yi-Tong Liu, Yang Yu, Zhi-Ran Yang, Yan Li

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Yan-Dong Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Mesothelioma, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To explore the most effective adjuvant chemotherapy regimen for malignant peritoneal mesothelioma (MPM) through patient derived tumor‐like cell clusters (PTC) drug sensitivity test.

Methods

PTC were cultured in vitro with intraoperative specimens, and drug sensitivity test was performed to calculate the most effective chemotherapy regimen for MPM. The patients were divided into conventional and individualized chemotherapy group according to whether they received PTC drug testing. Univariate and multivariate analyses were conducted to identify independent prognostic factors.

Results

Among 186 MPM patients included, 63 underwent PTC culture and drug sensitivity test. The results showed that the most effective chemotherapy regimen was oxaliplatin + gemcitabine. After propensity score matching, a total of 64 patients were enrolled in the following study, including 32 patients receiving individualized chemotherapy guided by PTC drug results as group 1 and 32 patients receiving conventional chemotherapy as group 2. Survival analysis showed that the median OS of group 1 was not reached, significantly longer than that of group 2 (23.5 months) ( p < 0.05).

Conclusions

Compared with conventional chemotherapy, individualized chemotherapy guided by PTC drug sensitivity tests can prolong patient survival, and oxaliplatin + gemcitabine + apatinib could be the optimal adjuvant treatment regimen for MPM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMesotheliomaLung NeoplasmsHumansFemaleMaleMiddle AgedDeoxycytidineOxaliplatinGemcitabineMesothelioma, MalignantAgedPrognosisSurvival RatePyridinesChemotherapy, AdjuvantAdultRetrospective Studies

Stichwörter der Autor:innen

drug testingmalignant peritoneal mesotheliomaoxaliplatin + gemcitabine + apatinibpatient derived tumor‐like cell clusterspropensity score matching

Substanzen

DeoxycytidineOxaliplatinGemcitabinePyridinesapatinib

Autor:innen und Institutionen

  • Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Su, Y. D., Ma, R., Fu, Y. B., Wu, H. L., Liang, X. L., Liu, Y. T., Yu, Y., Yang, Z. R., & Li, Y. (2024). Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27847

Vancouver

Su YD, Ma R, Fu YB, Wu HL, Liang XL, Liu YT, et al. Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27847

BibTeX
@article{Su2024,
  author = {Su, Yan-Dong and Ma, Ru and Fu, Yu-Bin and Wu, He-Liang and Liang, Xin-Li and Liu, Yi-Tong and Yu, Yang and Yang, Zhi-Ran and Li, Yan},
  title = {Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27847}
}
Kostenlos starten →